A61K 40/40
Cellular immunotherapy: characterised by antigens that are targeted or presented by cells
Official title: characterised by antigens that are targeted or presented by cells of the immune system
A61K40/40 (Cellular immunotherapy: characterised by antigens that are targeted or presented by cells) appears on 6,256 US grants and 14,113 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,256
- Published applications
- 14,113
- Assignees
- 3,151
- Inventors
- 16,992
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 5 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 6 | 0 |
| 1993 | 6 | 0 |
| 1994 | 9 | 0 |
| 1995 | 7 | 0 |
| 1996 | 6 | 0 |
| 1997 | 22 | 0 |
| 1998 | 39 | 0 |
| 1999 | 28 | 0 |
| 2000 | 36 | 0 |
| 2001 | 39 | 24 |
| 2002 | 62 | 169 |
| 2003 | 51 | 199 |
| 2004 | 47 | 196 |
| 2005 | 33 | 143 |
| 2006 | 68 | 168 |
| 2007 | 33 | 114 |
| 2008 | 65 | 172 |
| 2009 | 58 | 172 |
| 2010 | 106 | 227 |
| 2011 | 104 | 242 |
| 2012 | 100 | 187 |
| 2013 | 127 | 222 |
| 2014 | 145 | 284 |
| 2015 | 166 | 276 |
| 2016 | 185 | 346 |
| 2017 | 180 | 501 |
| 2018 | 269 | 651 |
| 2019 | 340 | 924 |
| 2020 | 494 | 1134 |
| 2021 | 509 | 1335 |
| 2022 | 536 | 1498 |
| 2023 | 532 | 1374 |
| 2024 | 626 | 1472 |
| 2025 | 712 | 1184 |
| 2026 | 490 | 899 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Influenza estem immunogens8 Oct 2026US 2026/0306612 A1
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005